A decade after the launch of the FDA Sentinel Initiative, it has matured from a pilot program designed to assess potential drug-safety signals in insurance claims into a core component of the agency’s evolving safety surveillance system.
No takes yet. Share an insight, caveat, or question.
Platt et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: